Joana Smirnovienė

Joana Smirnovienė

Auto-generated profile, based on publicly available information

Joana Smirnovienė

Department of Biothermodynamics and Drug Design Institute of Biotechnology Life Sciences Center Vilnius University Saulėtekio 7 Vilnius 10257 Lithuania

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
VDVirginija Dudutienė
Virginija Dudutienė
JMJurgita Matulienė
Jurgita Matulienė
Alexander SmirnovAlexander Smirnov
Alexander Smirnov
DTDavid D. Timm
David D. Timm
AZAsta Zubrienė
Asta Zubrienė
DMDaumantas Matulis
Daumantas Matulis

1 October 2015 in Biophysical Chemistry
Verified
Journal Article
Closed access
Asta ZubrieneAsta Zubriene
Asta Zubriene
JSJoana Smirnovienė
Joana Smirnovienė
Alexander SmirnovAlexander Smirnov
Alexander Smirnov
VMVaida Morkūnaitė
Vaida Morkūnaitė
VMVilma Michailovienė
Vilma Michailovienė
DMDaumantas Matulis
Daumantas Matulis

10 March 2015 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
VDVirginija Dudutienė
Virginija Dudutienė
AZAsta Zubrienė
Asta Zubrienė
Alexander SmirnovAlexander Smirnov
Alexander Smirnov
DTDavid D. Timm
David D. Timm
JSJoana Smirnovienė
Joana Smirnovienė
DMDaumantas Matulis
Daumantas Matulis

1 April 2017 in Analytical Biochemistry
Verified
Journal Article
Closed access
JSJoana Smirnovienė
Joana Smirnovienė
Vytautas SmirnovasVytautas Smirnovas
Vytautas Smirnovas
DMDaumantas Matulis
Daumantas Matulis

1 April 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
BBBenas Balandis
Benas Balandis
GIGuostė Ivanauskaitė
Guostė Ivanauskaitė
JSJoana Smirnovienė
Joana Smirnovienė
KKKristina Kantminienė
Kristina Kantminienė
DMDaumantas Matulis
Daumantas Matulis
Asta ZubrieneAsta Zubriene
Asta Zubriene

10 December 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MKMiglė Kišonaitė
Miglė Kišonaitė
Asta ZubrieneAsta Zubriene
Asta Zubriene
EČEdita Čapkauskaitė
Edita Čapkauskaitė
Alexander SmirnovAlexander Smirnov
Alexander Smirnov
JSJoana Smirnovienė
Joana Smirnovienė
DMDaumantas Matulis
Daumantas Matulis
The early stage of drug discovery is often based on selecting the highest affinity lead compound. To this end the structural and energetic characterization of the binding reaction is important. The binding energetics can be resolved into enthalpic and entropic contributions to the binding Gibbs free energy. Most compound binding reactions are coupled to the absorption or release of protons by the protein or the compound. A distinction between the observed and intrinsic parameters of the binding energetics requires the dissection of the protonation/deprotonation processes. Since only the intrinsic parameters can be correlated with molecular structural perturbations associated with complex formation, it is these parameters that are required for rational drug design. Carbonic anhydrase (CA) isoforms are important therapeutic targets to treat a range of disorders including glaucoma, obesity, epilepsy, and cancer. For effective treatment isoform-specific inhibitors are needed. In this work we investigated the binding and protonation energetics of sixteen [(2-pyrimidinylthio)acetyl]benzenesulfonamide CA inhibitors using isothermal titration calorimetry and fluorescent thermal shift assay. The compounds were built by combining four sulfonamide headgroups with four tailgroups yielding 16 compounds. Their intrinsic binding thermodynamics showed the limitations of the functional group energetic additivity approach used in fragment-based drug design, especially at the level of enthalpies and entropies of binding. Combined with high resolution crystal structural data correlations were drawn between the chemical functional groups on selected inhibitors and intrinsic thermodynamic parameters of CA-inhibitor complex formation.